Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24252898 | 0.93 | STING1 (0.31) | STING1ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL29015475 | 0.91 | STING1 (0.30) | STING1ESR1ESR2 | |
| SCHEMBL30451438 | 0.76 | — | — | |
| SCHEMBL24252421 | 0.76 | — | — | |
| SCHEMBL16646964 | 0.75 | AR (0.32) | — | |
| SCHEMBL4171951 | 0.75 | FLT1 (0.43) | — | |
| SCHEMBL27092843 | 0.75 | PDE10A (0.46) | — | |
| SCHEMBL12861090 | 0.74 | SRC (0.32) | — | |
| SCHEMBL29755712 | 0.73 | ESR1 (0.34) | ESR1ESR2 | |
| SCHEMBL23301479 | 0.73 | ESR1 (0.34) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4516318-A2 | 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-C] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | Suzhou Zanrong Pharma Limited (CN) | 2025-03-05 | — | — | EP | disclosed |
| US-12226414-B2 | 1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (ATM) kinase and uses thereof | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2025-02-18 | — | — | US | disclosed |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-115636833-B | Substituted imidazo [4,5-c ] cinnolin-2-one compounds as selective modulators of ATM kinases and uses thereof | 苏州赞荣医药科技有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20240207263-A1 | SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2024-06-27 | — | — | US | disclosed |
| CN-112469720-B | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | 艾科思莱德制药公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4308569-A1 | SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | Suzhou Zanrong Pharma Limited (CN) | 2024-01-24 | — | — | EP | disclosed |
| CN-117412972-A | Selective modulators of Ataxia Telangiectasia Mutated (ATM) kinase and uses thereof | 苏州赞荣医药科技有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20220047595-A1 | 1-ISOPROPYL-3-METHYL-8-(PYRIDIN-3-YL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-c]CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2022-02-17 | — | — | US | disclosed |
| US-20220047595-A1 | 1-ISOPROPYL-3-METHYL-8-(PYRIDIN-3-YL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-c]CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2022-02-17 | — | — | US | disclosed |
| EP-3849984-A1 | 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-C] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | Suzhou Zanrong Pharma Limited (CN) | 2021-07-21 | — | — | EP | disclosed |
| CN-112752758-A | 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2H-imidazo [4,5-c ] cinnolin-2-one as selective modulator of ataxia-telangiectasia mutated (ATM) kinase and uses thereof | 苏州赞荣医药科技有限公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-112469720-A | Dual ATM and DNA-PK inhibitors for use in antitumor therapy | 艾科思莱德制药公司 | 2021-03-09 | — | — | CN | disclosed |
| EP-3784671-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| WO-2020052688-A1 | 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-c] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020052688-A1 | 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-c] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2020-03-19 | — | — | WO | disclosed |
| WO-2019201283-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019201283-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047595-A1 | 1-ISOPROPYL-3-METHYL-8-(PYRIDIN-3-YL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-c]CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | ATM, CHEK2, CHEK1 | STING1 190/4885ESR1 4186/4885ESR2 3991/4885 |
| US-12226414-B2 | 1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (ATM) kinase and uses thereof | ATM, CHEK2, CHEK1 | STING1 190/4885ESR1 4186/4885ESR2 3991/4885 |
| US-20240207263-A1 | SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | ATM, CHEK2, CHEK1 | STING1 147/4885ESR1 3926/4885ESR2 3634/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | STING1 360/4885ESR1 3711/4885ESR2 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.